• LAST PRICE
    1.3200
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (2.3256%)
  • Bid / Lots
    1.2500/ 3
  • Ask / Lots
    1.3500/ 15
  • Open / Previous Close
    1.3300 / 1.2900
  • Day Range
    Low 1.2500
    High 1.3300
  • 52 Week Range
    Low 1.0500
    High 5.1950
  • Volume
    175,885
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.29
TimeVolumeIVVD
09:32 ET47981.32
09:36 ET8031.315
09:48 ET1001.33
09:50 ET4001.315
09:52 ET1001.31
09:54 ET1001.31
09:59 ET25171.31
10:01 ET1001.31
10:03 ET3001.315
10:08 ET1001.31
10:12 ET2001.295
10:19 ET13891.28
10:26 ET3001.27
10:28 ET13001.27
10:30 ET10111.265
10:32 ET6001.26
10:33 ET13621.26
10:35 ET2691.26
10:39 ET23971.275
10:42 ET2001.275
10:44 ET1251.2799
10:46 ET6101.28
10:50 ET5441.27
10:53 ET17691.265
10:55 ET4561.27
10:57 ET1001.275
11:08 ET3001.27
11:11 ET2501.275
11:13 ET5001.275
11:15 ET2001.27
11:18 ET3001.265
11:20 ET2001.265
11:22 ET1001.265
11:24 ET3001.27
11:26 ET1001.28
11:31 ET5571.2899
11:33 ET1001.285
11:38 ET1001.285
11:40 ET1001.29
11:42 ET1001.285
11:45 ET36001.295
11:47 ET1001.295
11:49 ET2761.29
11:56 ET16401.29
11:58 ET2001.29
12:00 ET2001.295
12:12 ET1001.29
12:14 ET4001.29
12:20 ET1001.29
12:21 ET3001.29
12:25 ET6001.3
12:27 ET2001.29
12:30 ET3301.29
12:32 ET1001.295
12:34 ET3001.295
12:36 ET1001.2905
12:39 ET1001.29
12:43 ET3001.295
12:45 ET1001.295
12:48 ET2501.2996
12:50 ET1001.295
12:57 ET10361.295
01:01 ET3001.3
01:03 ET5001.29
01:06 ET1001.295
01:08 ET1001.29
01:10 ET2001.295
01:12 ET2001.2901
01:15 ET4221.28
01:19 ET21001.275
01:21 ET19651.29
01:30 ET2701.2803
01:32 ET2001.285
01:33 ET7001.285
01:35 ET10001.275
01:37 ET1001.275
01:39 ET2001.275
01:42 ET17001.285
01:44 ET1001.285
01:48 ET33021.285
01:50 ET10001.285
01:51 ET1001.28
01:53 ET7001.28
01:55 ET1001.285
01:57 ET2001.28
02:04 ET15151.295
02:06 ET5791.299
02:08 ET1001.29
02:13 ET10001.291
02:15 ET4271.295
02:20 ET30101.29
02:22 ET8001.28
02:24 ET45811.295
02:27 ET10001.29
02:29 ET1331.3
02:36 ET12461.29
02:38 ET1001.29
02:40 ET7001.29
02:44 ET5521.295
02:51 ET1001.29
02:54 ET1001.295
02:56 ET1001.29
02:58 ET5001.295
03:00 ET3901.2901
03:02 ET15921.295
03:03 ET1001.295
03:05 ET1001.29
03:07 ET8001.285
03:09 ET1001.28
03:12 ET15241.295
03:16 ET5131.2993
03:20 ET9231.29
03:21 ET2001.29
03:25 ET2001.29
03:27 ET31451.3
03:30 ET15001.3
03:32 ET4001.3
03:34 ET1001.295
03:36 ET13001.295
03:38 ET1001.295
03:39 ET10521.295
03:41 ET1001.295
03:43 ET5001.29
03:45 ET10131.295
03:48 ET37631.305
03:50 ET19091.305
03:52 ET39521.315
03:54 ET11001.315
03:56 ET6391.31
03:57 ET28951.31
03:59 ET67731.32
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIVVD
Invivyd Inc
153.9M
-0.7x
---
United StatesRANI
Rani Therapeutics Holdings Inc
152.7M
-2.3x
---
United StatesATYR
aTyr Pharma Inc
153.9M
-2.5x
---
United StatesDMAC
DiaMedica Therapeutics Inc
157.7M
-6.6x
---
United StatesELEV
Elevation Oncology Inc
157.9M
-2.8x
---
United StatesGALT
Galectin Therapeutics Inc
158.5M
-3.5x
---
As of 2024-07-26

Company Information

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Contact Information

Headquarters
1601 Trapelo Road, Suite 178WALTHAM, MA, United States 02451
Phone
781-819-0080
Fax
302-655-5049

Executives

Independent Chairman of the Board
Marc Elia
Principal Executive Officer, Chief Financial Officer
William Duke
Chief Human Resource Officer
Julie Green
Chief Technology and Manufacturing Officer
Stacy Price
Chief Scientific Officer
Robert Allen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$153.9M
Revenue (TTM)
$0.00
Shares Outstanding
119.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.86
Book Value
$1.61
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.